Minutes of Extraordinary General Meeting CS MEDICA A/S

An Extraordinary General Meeting of CS MEDICA A/S (the “Company”) was held on 30 April 2026 at 15:30 (CET) at Indiakaj 10, 2nd floor, DK-2100 Copenhagen Ø, Denmark.

The meeting was opened, and Gitte Lund Henriksen was elected as chairman of the meeting. The chairman noted that shareholders representing 62.2% of the total share capital and voting rights, totally 19,026,344 votes, were present at the meeting and that the Extraordinary General Meeting had been duly convened and was quorate.

Agenda:

1. Approval of the Annual Report
The Annual Report for the financial year 1 October 2024 – 30 September 2025, which was not adopted at the Annual General Meeting held on 31 March 2026 due to an ongoing audit process, was presented.

The Annual Report showed a net loss of DKK 12,553,297 and equity of DKK -4,068,202 as at 30 September 2025.

The Annual Report was adopted unanimously.

2. Resolution on appropriation of result
The General Meeting resolved to appropriate the result for the year in accordance with the proposal set out in the Annual Report.

There being no further business, the chairman declared the meeting closed.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/
 

About CS MEDICA A/S
Founded in 2011, CS MEDICA is a Danish MedTech company specializing in CBD-infused treatments for autoimmune and stress-related conditions, including arthritis, psoriasis, and pain management. Operating at the intersection of the pharmaceutical and cosmetics industries, CS MEDICA delivers clinically supported products with fewer side effects, offering competitive and accessible alternatives. With MDR-approved products, cutting-edge R&D, and the benefits of CBD, the company provides innovative, safe, and effective solutions. Its capital-light business model and trusted European production partners further enhance its ability to offer high-quality treatments, setting CS MEDICA apart in the MedTech sector.